BRIEF published on 09/08/2026 at 22:05, 25 days 3 hours ago Inventiva présente ses avancées lors du Congrès Paris MASH 2026 Inventiva MASH Lanifibranor Phase Clinique PPAR
BRIEF published on 09/08/2026 at 22:05, 25 days 3 hours ago Inventiva to Showcase Lanifibranor Data at Paris MASH 2026 Clinical Data Inventiva MASH Lanifibranor PPAR Agonist
BRIEF published on 09/08/2026 at 22:05, 25 days 3 hours ago Inventiva présentera les données de Lanifibranor au salon Paris MASH 2026 Inventive Lanifibranor Données Cliniques ÉCRASER Agoniste PPAR
BRIEF published on 09/08/2026 at 22:05, 25 days 3 hours ago Inventiva presents its advancements at the Paris MASH 2026 Congress Inventiva MASH Lanifibranor Clinical Phase PPAR
PRESS RELEASE published on 09/08/2026 at 22:00, 25 days 3 hours ago Inventiva to Present Multiple Abstracts at Paris MASH 2026 Inventiva to present Phase 1 and Phase 2 clinical data on lanifibranor at Paris MASH 2026, showing improvements in metabolic and cardiovascular factors in MASH patients. Lanifibranor's pan-PPAR pharmacology highlighted Clinical Data Inventiva Lanifibranor Metabolic Dysfunction Paris MASH 2026
PRESS RELEASE published on 09/08/2026 at 22:00, 25 days 3 hours ago Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026 Inventiva présentera plusieurs abstracts au Congrès Paris MASH 2026, illustrant l'amélioration du profil métabolique et cardiovasculaire par le lanifibranor chez les patients atteints de MASH Études Cliniques Inventiva Lanifibranor Paris MASH 2026 Phase 1 Et Phase 2
BRIEF published on 09/02/2026 at 22:10, 1 month 1 day ago Inventiva Completes Key Milestone in MASH Clinical Trial Biopharmaceutical Inventiva Lanifibranor MASH Treatment NATiV3 Trial
BRIEF published on 09/02/2026 at 22:10, 1 month 1 day ago Inventiva Achève la Visite Finale de l'Étude NATiV3 sur le Lanifibranor Étude Clinique Phase 3 Inventiva MASH Lanifibranor
BRIEF published on 09/02/2026 at 22:10, 1 month 1 day ago Inventiva Completes Final Visit of the NATiV3 Lanifibranor Study Clinical Study Phase 3 Inventiva MASH Lanifibranor
Published on 10/03/2026 at 02:35, 23 hours 16 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 1 day 12 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 12 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 12 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 10 hours 6 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 1 hour ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 5 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 6 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 1 day 6 hours ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 17:45, 1 day 8 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 1 day 8 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 1 day 8 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 1 day 8 hours ago Aéroports de Paris SA - Calendrier financier 2027
